Atrial Fibrillation Patient Preference Study

Bayer382 enrolled

Overview

The main research question of this patient survey is to assess AF patients' preferences associated with different attributes which describe the different available anticoagulation treatment options (VKA or NOACs and, in case of NOACs, Apixaban, Dabigatran or Rivaroxaban). VKA (Waran®) will be compared to Rivaroxaban.

The objective of this study is to investigate the following research questions in a cross-sectional survey of Swedish AF patients being treated either with a VKA or with a NOAC: * Which attributes of a medication to prevent stroke do AF patients view as important? * Do AF patients have a preference regarding the attributes of the medication options VKA or NOAC and, in case of NOACs, with regards to rivaroxaban attributes? * Are there subgroups of AF patients whose preference for one of the medication options appears above or below average? * What is the quality of life of Swedish AF patients? Are there subgroups with differences in their quality of life (for example: subgroups of patients with different CHA2DS2-VASc scores)? * Which burden do Swedish AF patients experience in association with their anticoagulation therapy? Are there differences in the burden of treatment (ACTS) between patients treated with VKA or with NOACs?

Study Type

OBSERVATIONAL

Enrollment

382

Conditions

Atrial Fibrillation

Interventions

VKA: Warfarin (Waran)DRUG

VKA have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)

NOAC: Rivaroxaban (Xarelto, BAY59-7939)DRUG

NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: Inclusion criteria for AF patients in both the NOAC and the VKA groups: * Patients with a confirmed diagnosis of nonvalvular atrial fibrillation (persistent, paroxysmal, permanent), * Age of at least 18 years at time of study inclusion, * Generally willingness (informed consent) and ability to fill out a survey on satisfaction with treatment and quality of life, and to conduct a structured phone interview (approx. 20 - 30 min) in Swedish language. Additional inclusion criterion for Group 1 (NOAC): * Continuous anticoagulation with either Apixaban, or Dabigatran or Rivaroxaban for prevention of Stroke \& systemic embolism for at least the previous 3 months. Additional inclusion criterion for Group 2 (VKA): * Continuous anticoagulation with a VKA for prevention of Stroke \& systemic embolism for at least the previous 3 months. Exclusion Criteria: Exclusion criteria for both groups: * Participation in another

Locations (1)

Unnamed facility

Multiple Locations, Sweden

Outcomes

Primary Outcomes

AF patients'preferences towards anticoagulation treatment with either VKAs or NOACs measured with a DCE (discrete choice experiment) design in a phone interview: Frequency of intake (once/twice daily)